Silvia Ling

3PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Dec 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos

|Jun 03, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Sikander Ailawadhi, Ivan Špička, Andrew Spencer

|Oct 20, 2020
Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres.

Georgia J McCaughan, Anvita Verma, Silvia Ling

Pageof 1

Frequent Collaborators

2 joint publications

Meletios-Athanasios Dimopoulos

2 joint publications

María-Victoria Mateos

1 joint publications

Georgia J McCaughan

1 joint publications

Sikander Ailawadhi